Deal will utilize Dyax’ phage display libraries to find compounds that bind to Trubion’s targets in oncology and inflammation.
Dyax entered into a nonexclusive agreement with Trubion Pharmaceuticals in the fields of protein therapeutics and diagnostics discovery. Under the agreement, Dyax will utilize its phage display libraries for the discovery of compounds that bind with high affinity and specificity to Trubion’s targets in the oncology and inflammation area.
Dyax will receive upfront and FTE payments from Trubion, as well as technical and development milestone payments and royalties on net sales of any products that may result from Trubion’s development and commercialization of binding regions from Dyax’ libraries. The agreement also provides Trubion with an option to license Dyax’ phage display libraries.